Advice
Following a full submission
Insulin glulisine (Apidra) is accepted for restricted use within NHS Scotland for the treatment of adult patients with diabetes mellitus in whom treatment with a short-acting insulin analogue is appropriate.
Insulin glulisine has similar efficacy to other short-acting insulins in reducing glycated haemoglobin and a similar pharmacokinetic profile to at least one other insulin analogue. It is restricted to use in patients where regular human insulin is inappropriate.
Download detailed advice46KB (PDF)
Medicine details
- Medicine name:
- insulin glulisine for subcutaneous injection 100 units/ml (Apidra)
- SMC ID:
- 298/06
- Indication:
- Diabetes mellitus
- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 11 September 2006